GNH USA

Europe — EMA

Mycophenolate Mofetil Teva

GNH USA supplies Mycophenolate Mofetil Teva (Mycophenolate Mofetil), an immunosuppressant for prevention of organ transplant rejection and treatment of lupus

Request sourcing

1
Pack/s

What is Mycophenolate Mofetil?

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Teva, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis by dampening immune activity in transplant recipients and patients with renal lupus.

GNH USA supplies Mycophenolate Mofetil Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

What is Mycophenolate Mofetil used for?

Mycophenolate Mofetil is used in immunosuppressive regimens for several transplant and autoimmune conditions. - Kidney transplant: reduces the risk of acute and chronic graft rejection. - Liver transplant: helps maintain graft function by suppressing immune‑mediated injury. - Lupus nephritis: controls renal inflammation and preserves kidney function.

What are the side effects of Mycophenolate Mofetil?

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, may lead to dehydration. - Headache: transient cranial discomfort. - Upper respiratory infection: increased susceptibility to common colds.

Serious or Rare Side Effects: - Bone marrow suppression: leukopenia, anemia, or thrombocytopenia. - Severe infections: opportunistic bacterial, viral, or fungal infections. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Teratogenicity: risk of fetal malformations and pregnancy loss.

What precautions apply to Mycophenolate Mofetil?

Patients receiving Mycophenolate Mofetil require careful monitoring and counseling. - Monitor blood counts: check complete blood count regularly for marrow suppression. - Assess renal function: adjust therapy if creatinine rises. - Avoid live vaccines: immunosuppression can cause vaccine‑derived infection. - Contraindicated in pregnancy: drug is teratogenic; effective contraception is mandatory. - Use contraception: both male and female patients should employ reliable birth control. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

What does Mycophenolate Mofetil interact with?

Mycophenolate Mofetil can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine: increased mycophenolic acid exposure, raising toxicity risk. - Tacrolimus: synergistic immunosuppression, may require dose adjustment.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation. - ACE inhibitors: may exacerbate renal impairment, watch creatinine. - NSAIDs: increase risk of gastrointestinal bleeding and renal dysfunction.

Frequently asked questions

What conditions is Mycophenolate Mofetil Teva used for?+
Mycophenolate Mofetil Teva is prescribed to prevent rejection of transplanted organs such as kidneys and livers, and to treat lupus nephritis, a kidney manifestation of systemic lupus erythematosus. It works by suppressing the immune system to protect the graft and reduce renal inflammation.
How does Mycophenolate Mofetil work in the body?+
The drug is a pro‑drug that is converted to mycophenolic acid, which inhibits the enzyme inosine monophosphate dehydrogenase. This blocks the synthesis of guanosine nucleotides needed for lymphocyte proliferation, thereby reducing the activity of T‑ and B‑cells that drive immune responses.
What is the usual dose of Mycophenolate Mofetil Teva?+
The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s transplant type, renal function, and overall health. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without deviation.
Is Mycophenolate Mofetil safe during pregnancy or breastfeeding?+
Mycophenolate Mofetil is classified as Pregnancy Category X because it can cause fetal malformations and pregnancy loss. It is contraindicated in pregnant women and should be discontinued before conception. Breastfeeding is not recommended as the drug is excreted in milk.
How do I order Mycophenolate Mofetil Teva from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Mycophenolate Mofetil compare with other immunosuppressants?+
Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, Mycophenolate Mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcium signaling. It is often used in combination regimens to provide synergistic immunosuppression while allowing lower doses of each agent, potentially reducing individual drug toxicity.
What are the recommended storage conditions for Mycophenolate Mofetil Teva?+
The product should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, heat, and direct sunlight. Do not refrigerate or freeze unless the packaging specifically indicates otherwise.
How is Mycophenolate Mofetil Teva administered?+
Mycophenolate Mofetil Teva is taken orally, usually with food or a glass of water to lessen gastrointestinal irritation. The tablets are swallowed whole and should not be crushed or chewed unless directed by a healthcare professional.
What are the most serious risks associated with Mycophenolate Mofetil?+
Serious risks include bone‑marrow suppression leading to low blood counts, severe infections due to immunosuppression, liver toxicity, and teratogenic effects that can cause birth defects. Patients should be monitored regularly for these complications and report any concerning symptoms promptly.
Who should not use Mycophenolate Mofetil Teva?+
The drug is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate or its components, and patients with severe uncontrolled infections. Caution is also advised for those with significant renal or hepatic impairment, and live vaccines should be avoided.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Mycophenolate Mofetil
Route
Oral Use
Manufacturer
Teva B.V
Origin
EU

Related products